Oral contraceptive pretreatment significantly reduces ongoing pregnancy likelihood in gonadotropin-releasing hormone antagonist cycles: an updated meta-analysis

• Published in: Fertility and sterility Vol. 94; no. 6; pp. 2382 - 2384
• Main Authors: Griesinger, Georg, M.D., Ph.D, Kolibianakis, Efstratios Michaelis, M.D., Ph.D, Venetis, Christos, M.D., M.Sc, Diedrich, Klaus, M.D., Ph.D, Tarlatzis, Basil, M.D., Ph.D
• Format: Journal Article
• Language: English
• Published: New York, NY Elsevier Inc 01.11.2010; Elsevier
• Subjects: antide; Biological and medical sciences; Birth control; cetrorelix; Contraceptives, Oral - administration & dosage; Contraceptives, Oral - adverse effects; Drug Administration Schedule; Female; Fertility Agents, Female - administration & dosage; Fertility Agents, Female - adverse effects; ganirelix; GnRH antagonists; Gonadotropin-Releasing Hormone - antagonists & inhibitors; Gynecology. Andrology. Obstetrics; Hormone Antagonists - administration & dosage; Humans; Internal Medicine; Likelihood Functions; Medical sciences; Obstetrics and Gynecology; Odds Ratio; oral contraceptive pill; ovarian stimulation; Pregnancy - drug effects; Pregnancy - statistics & numerical data; Pregnancy Rate; Randomized Controlled Trials as Topic - methods; Sterility. Assisted procreation; GnRH antagonists; ganirelix; antide; cetrorelix; oral contraceptive pill; ovarian stimulation; Ovarian stimulation; Decapeptide; Peptides; Gynecology; Oral administration; Gonadotropin RH; Assisted procreation; Antihormone; Obstetrics; Ganirelix; Pregnancy; Contraceptive; Antagonist; Pretreatment; Pill; Cetrorelix
• ISSN: 0015-0282; 1556-5653
• DOI: 10.1016/j.fertnstert.2010.04.025

Ongoing pregnancy rate (PR) per randomized woman was found to be significantly lower in patients with oral contraceptive (OC) pill pretreatment (relative risk: 0.80, 95% confidence interval [CI]: 0.66–0.97; rate difference: -5%, 95% CI: -10% to -1%; fixed effects model) after pooling data from six randomized controlled trials encompassing 1,343 patients. Duration of stimulation (weighted mean difference [WMD]: +1.33 days, 95% CI: +0.61–2.05) and gonadotropin consumption (WMD: +360 IUs, 95% CI: +158–563) were significantly increased after OC pretreatment, but there was no statistically significant gain in the number of cumulus-oocyte complexes (WMD: +0.6 cumulus-oocyte complexes, 95% CI: -0.08–1.25).